Highlights
- DSM reports a good H1
- Results compared to Underlying business in H1 2018:
- Group sales +3%, Adjusted EBITDA up 12% (including 3% from IFRS 16)
- Nutrition: organic sales +4%, Adjusted EBITDA up 13% (including 2% from IFRS 16)
- Materials: organic sales -6%, Adjusted EBITDA flat (including 1% from IFRS 16)
- Adjusted Net Operating Free Cash Flow €257m, up 14% versus H1 2018
- Total Net profit €401m, up versus H1 2018 of €633m when correcting for the temporary vitamin effect of €275m EBITDA following an exceptional supply disruption in the industry
- Interim dividend of €0.77 per ordinary share
- Full year outlook maintained
Key figures and indicators
| in € million | H1 2019 | H1 2018 | % change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Underlying business |
Temporary vitamin effect |
Total Group |
Underlying Organic growth |
FX & ‘other’ |
Underlying total growth |
Temporary vitamin effect |
Total Group |
||
| Sales | 4,568 | 4,429 | 365 | 4,794 | 1% | 2% | 3% | -8% | -5% |
| Nutrition | 3,029 | 2,840 | 365 | 3,205 | 4% | 3% | 7% | -12% | -5% |
| Materials | 1,427 | 1,492 | 1,492 | -6% | 2% | -4% | -4% | ||
| Adjusted EBITDA | 862 | 771 | 275 | 1,046 | 12% | -30% | -18% | ||
| Nutrition | 639 | 564 | 275 | 839 | 13% | -37% | -24% | ||
| Materials | 262 | 261 | 261 | 0% | 0% | ||||
| Innovation | 11 | 0 | 0 | ||||||
| Corporate | -50 | -54 | -54 | ||||||
| EBITDA | 823 | 754 | 275 | 1029 | |||||
| Adjusted EBITDA margin | 18.9% | 17.4% | 21.8% | ||||||
CEO statement
Feike Sijbesma, CEO/Chairman DSM Managing Board, commented: “I am pleased to report a good performance for the first half year, achieved against a challenging macro-economic environment. The Nutrition business saw continued good business conditions and delivered a strong performance, demonstrating the quality of its innovative portfolio of value-added solutions. Materials experienced ongoing soft market conditions in some of its end-markets, especially in China. Through a continued strong performance in the Dyneema and Functional Materials businesses, combined with good margin management, our Materials business demonstrated resilience with stable earnings.
DSM continues to be well positioned to deliver on our ambitious Strategy 2021 targets, driven by our commitment to be a purpose led, performance driven science-based company in Nutrition, Health and Sustainable Living. We reiterate our outlook for the full year.”
Q2 Highlights
- DSM reports another good quarter
- Results compared to Underlying business in Q2 2018:
- Group sales +3%, Adjusted EBITDA up 10% (including 3% impact from IFRS 16)
- Nutrition: organic sales +4%, Adjusted EBITDA up 13% (including 3% impact from IFRS 16)
- Materials: organic sales -7%, Adjusted EBITDA flat (including 1% impact from IFRS 16)
Key figures and indicators
| in € million | Q2 2019 | Q2 2018 | % change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Underlying business |
Temporary vitamin effect |
Total Group |
Underlying Organic growth |
FX & ‘other’ |
Underlying total growth |
Temporary vitamin effect |
Total Group |
||
| Sales | 2,276 | 2,214 | 145 | 2,359 | 1% | 2% | 3% | -7% | -4% |
| Nutrition | 1,512 | 1,410 | 145 | 1,555 | 4% | 3% | 7% | -10% | -3% |
| Materials | 710 | 754 | 754 | -7% | 1% | -6% | -6% | ||
| Adjusted EBITDA | 438 | 398 | 110 | 508 | 10% | -24% | -14% | ||
| Nutrition | 323 | 287 | 110 | 397 | 13% | -32% | -19% | ||
| Materials | 135 | 135 | 135 | 0% | 0% | ||||
| Innovation | 5 | 1 | 1 | ||||||
| Corporate | -25 | -25 | -25 | ||||||
| EBITDA | 407 | 393 | 110 | 503 | |||||
| Adjusted EBITDA margin | 19.2% | 18.0% | 21.5% | ||||||
Outlook 2019
DSM maintains its full year outlook as provided at Q1 2019: DSM expects to deliver a full year 2019 high single digit increase in Adjusted EBITDA compared to prior year Underlying Adjusted EBITDA (pre-temporary vitamin effect), together with an improvement in Underlying Adjusted Net Operating Free Cash Flow in line with its Strategy 2021 targets. This outlook excludes the impact of IFRS 16.
Share Buy-Back program
On 1 April 2019, DSM commenced its ordinary share repurchase program of an aggregate market value of €1 billion, with the intention to reduce its issued capital, as first announced on 14 February 2019. This program is in addition to the regular repurchase programs to cover commitments under share-based compensation plans and the stock dividend. As per 30 June DSM has repurchased 2.6 million shares for a total consideration of €265 million; 2 million shares relate to the regular repurchase programs and 0.6 million shares relate to the €1 billion share buy-back program.
